Nowy Sacz

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

Researchers are evaluating ELVN-001, a new drug, in adults with chronic myeloid leukemia (CML), including those with or without a specific T315I mutation. This early phase 1a/1b study aims to find the best dose of ELVN-001 for future studies by assessing its safety, tolerability, and how the body processes the drug. The study also looks at changes in a key leukemia marker called BCR-ABL1 to gather initial evidence of the drug's effect on CML. Participants will receive ELVN-001 orally once or twice daily. The trial includes a dose escalation period to identify recommended doses for further research. This first-in-human study will monitor patients closely to understand the safety profile and pharmacokinetics of ELVN-001. The drug is being tested in patients who have relapsed, are resistant, or cannot tolerate other tyrosine kinase inhibitors (TKIs). Throughout the study, participants will be monitored for adverse events, dose-limiting toxicities, and any significant lab or heart test abnormalities up to 28 days in phase 1a and for up to 3 years in phase 1b. Researchers will assess safety, tolerability, and leukemia markers regularly. The total duration of monitoring allows for a thorough evaluation of ELVN-001's effects and safety in adults with chronic phase CML.

Researchers are evaluating the effectiveness and safety of efgartigimod given through intravenous infusion in adults with primary immune thrombocytopenia (ITP), a condition characterized by low platelet counts. This Phase 3 trial includes participants who have had ITP for over a year and have previously received treatments like corticosteroids or immunoglobulins but had insufficient responses. The study aims to measure disease control by tracking the number of weeks during which platelet counts remain at or above 50 x 10^9/L over a 24-week treatment period. After a screening period of up to 2 weeks, participants are randomly assigned in a 2:1 ratio to receive either efgartigimod IV or a placebo IV during a 24-week double-blinded treatment period. Following this, all participants enter a 52-week open-label treatment phase where everyone receives efgartigimod IV. Those who complete this phase may continue for an additional 52 weeks in a second open-label treatment period. After finishing these treatment phases, participants undergo an approximately 8-week follow-up period without the study drug. Throughout the study, participants will have their platelet counts regularly monitored to assess the extent of disease control. Researchers will also evaluate safety and monitor participants for any medical conditions that might affect the study results or their well-being. The total duration of participation can be up to 138 weeks, including screening, treatment, and follow-up periods.

Researchers are evaluating the safety and effectiveness of robotically assisted percutaneous coronary intervention (PCI) using the CorPath GRX System in treating patients with coronary artery disease, including stable conditions, unstable angina, and acute myocardial infarction. This retrospective registry collects data from real-world clinical practice across Europe and Asia to better understand this innovative robotic approach. The study focuses on the use of the CorPath GRX System, a robotic platform designed to assist with the remote delivery and manipulation of guidewires, catheters, and guide catheters during PCI procedures. It includes a bedside robotic arm and a remote workstation, which together provide automated movements intended to improve procedural success, reduce procedure time, and enhance operator comfort. Patients included are those who underwent at least one robotic procedural step with this system and have completed one-year follow-up. Participants will have their baseline, procedural, and follow-up data collected to assess outcomes such as the number of participants with clinically successful PCI from the time of the procedure until hospital discharge or death. The study plans to enroll at least 700 patients, monitoring safety and efficacy through this comprehensive data collection over a one-year period after the intervention.

This research aims to evaluate the safety, effectiveness, and clinical results of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) in patients treated in routine clinical practice in Poland. It focuses on rates of procedural success, complications, different PCI strategies and techniques, and the impact of artificial intelligence-based analysis on predicting outcomes and quality of life. The study includes a variety of patient subgroups, including those at higher risk due to conditions like low ejection fraction or diabetes. Patients receiving CTO PCI as part of their usual medical care will be enrolled in a national, multicenter registry. The study will observe different treatment strategies such as drug-coated balloons, drug-eluting stents, and hybrid approaches. It will also assess the use of intravascular imaging and mechanical circulatory support during PCI, examining how these factors relate to clinical outcomes. Participants will have clinical, procedural, and follow-up data collected to assess real-world results. Researchers will monitor procedural success within one day and track complications and cardiac injury markers after treatment. The study will analyze quality-of-life improvements and outcomes in high-risk groups over time, providing a comprehensive view of CTO PCI in contemporary practice.

Researchers are evaluating whether adding navtemadlin to ruxolitinib treatment provides more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have not responded well to ruxolitinib alone. This Phase 3, randomized, double-blind study focuses on patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis. Participants must be JAK inhibitor-naive and have a suboptimal response to ruxolitinib treatment during the initial run-in period. During the study, all subjects start by receiving ruxolitinib alone in a run-in period. Those showing a suboptimal response are then randomly assigned in a 2:1 ratio to receive either navtemadlin or a navtemadlin placebo as an add-on to their ongoing ruxolitinib treatment. The study is blinded, so neither the participants nor the doctors know who is receiving the navtemadlin or placebo. Navtemadlin is an investigational MDM2 inhibitor, while ruxolitinib is a janus kinase 1/2 inhibitor. Participants are involved in assessments to compare spleen volume reduction and total symptom score reduction between the two treatment groups over 24 weeks. Researchers monitor safety and efficacy through clinical evaluations, symptom tracking, and laboratory tests. The study includes screening for performance status, blast counts, and TP53 wild-type status, ensuring participants meet specific health criteria before randomization.